ALK Gene Fusions and ROS1 Gene Fusions Detection Kit
PCR
Real-time PCR Assays
25 copies/μL
Sensitivity
100%
100%
Specificity
Features
Selectable
- Convenient pre-loaded format.
1
- Convenient pre-loaded format.
Universal
- Compatible with tissue samples.
2
- Compatible with tissue samples.
Precise
- Top sensitivity of 125 copies/rxn (ALK/ROS1).
3
- Top sensitivity of 125 copies/rxn (ALK/ROS1).
Easy
- One-step procedure, results in 120 mins.
4
- One-step procedure, results in 120 mins.
Reliable
- Internal and external controls included.
5
- Internal and external controls included.
Product Description

ALK Gene Fusions and ROS1 Gene Fusions Detection Kit

ALK gene fusions and ROS1 gene fusions define unique molecular subsets of non-small-cell lung cancer (NSCLC). EML4, KIF5B, TFG, KLC1 etc., are identified as fusion partners of ALK; SLC34A2, CD74, SDC4, EZR etc., are identified as fusion partners of ROSE These fusions lead to constitutive kinase activity and activation of downstream pathways, leading to carcinogenesis. It has been reported that the presence of the ALK gene fusions and ROS1 gene fusions are correlated with the efficacy of TKI therapy. Based on analysis of tumor messenger RNA, ALK gene fusions and ROS1 gene fusions can be detected by real-time PCR method.

Intended Use

The AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit is a real-time PCR assay for qualitative detection of 14 ALK gene fusions and 14 ROS1 gene fusions in human total RNA extracted from NSCLC formalin-fixed paraffin-embedded (FFPE) tumor tissue.

The kit is for in vitro diagnostic use, and intended to be used by trained professionals in a laboratory environment.

Download
Testing Procedure
Compatible Sample Types:FFPE Samples
Compatible Real-time PCR Instrument
ABI 7500
LightCycler 480 II
SLAN-96S
Stratagene Mx3000P™
Other Info.

To order, please contact sales@amoydx.com.

 Product Name

Type

Size (test/kit)

 Storage

ALK fusions and ROS1 fusions Detection Kit

Pre-loaded

8

-20℃


Publications
1. Zhang, Qing, et al. "Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer." Thoracic cancer 10.1 (2019): 47-53.

Certificate
BACK
Inquiry
Inquiry
* Required information
Manage your account info
Change your password